Tag Archives: NASDAQ:SELB

Selecta Biosciences (SELB) Receives a Buy from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.41, close to its 52-week low

Needham Remains a Buy on Selecta Biosciences (SELB)

Needham analyst Chad Messer maintained a Buy rating on Selecta Biosciences (SELB – Research Report) today and set a price target of $9.00. The company’s shares closed last Monday at $1.40, close to its 52-week low of $1.28. According to

Mizuho Securities Thinks Selecta Biosciences’ Stock is Going to Recover

Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (SELB – Research Report) on August 9 and set a price target of $4. The company’s shares closed on Friday at $1.80, close to its 52-week low of

Stifel Nicolaus Thinks Selecta Biosciences’ Stock is Going to Recover

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB – Research Report), with a price target of $6. The company’s shares opened today at $1.85, close to its 52-week low of

Mizuho Securities Reaffirms Their Buy Rating on Selecta Biosciences (SELB)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (SELB – Research Report) today and set a price target of $4. The company’s shares closed yesterday at $2.40, close to its 52-week low of $1.41. Yang observed:

Stifel Nicolaus Keeps a Buy Rating on Selecta Biosciences (SELB)

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB – Research Report), with a price target of $7. The company’s shares opened today at $2.22, close to its 52-week low of